Surface treatment of medical device

• US 20040116310A1
• Filed: 12/17/2002
• Published: 06/17/2004
• Est. Priority Date: 12/17/2002
• Status: Active Grant

• Current Assignee: Bausch & Lomb Incorporated (Bausch Health Cos., Inc.)
• Original Assignee: Bausch & Lomb Incorporated (Bausch Health Cos., Inc.)
• Inventors: McGee, Joseph A., Kunzler, Jay F., Salamone, Joseph C., Seelye, David E.
• Granted Patent: US 6,958,169 B2
• Time in Patent Office: Days
• US Class Current: 510/115
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials

Abstract

A method for improving the wettability of a medical device involves: (a) providing a medical device formed from a monomer mixture comprising a hydrophilic device-forming monomer including a copolymerizable group and an electron donating moiety, and a second device-forming monomer including a copolymerizable group and a reactive functional group; and (b) contacting a surface of the medical device with a wetting agent including a proton donating moiety reactive with the functional group provided by the second lens-forming monomer and that complexes with the electron donating moiety provided by the hydrophilic lens-forming monomer.

Claims

1. A method for improving the wettability of a medical device, comprising:

(a) providing a medical device formed from a monomer mixture comprising a hydrophilic device-forming monomer including a copolymerizable group and an electron donating moiety, and a second device-forming monomer including a copolymerizable group and a reactive functional group; and

(b) contacting a surface of the medical device with a wetting agent including a proton donating moiety reactive with the functional group provided by the second lens-forming monomer and that complexes with the electron donating moiety provided by the hydrophilic lens-forming monomer.

2. The method of claim 1, wherein the wetting agent comprises proton donating moieties selected from the group consisting of carboxylic acids, sulfonic acids, fumaric acids, maleic acids, anhydrides, and vinyl alcohols.

3. The method of claim 1 wherein said wetting agent comprises a polymer containing carboxylic acid reactive groups.

4. The method of claim 1, wherein the medical device comprises a silicone hydrogel, and the monomer mixture further comprises a silicone-containing device-forming monomer.

5. The method of claim 1, wherein the hydrophilic monomer is selected from the group consisting of vinyl lactams, acrylamides, vinyl carbonates, vinyl carbamates, and oxazolones.

6. The method of claim 5, wherein the hydrophilic monomer includes at least one member selected from the group consisting of N-vinylpyrrolidone and N,N-dimethylacrylamide.

7. The method of claim 1, wherein the second device-forming monomer includes a copolymerizable ethylenically unsaturated group and an epoxy reactive functional group.

8. The method of claim 7, wherein the second device-forming monomer is selected from the group consisting of glycidyl methacrylate, glycidyl acrylate, glycidyl vinylcarbonate, and glycidyl vinylcarbamate.

9. The method of claim 1, wherein the medical device has not been subjected to a surface oxidation treatment.

10. The method of claim 9, wherein the wetting agent forms a complex with the hydrophilic monomer in the absence of a surface oxidation treatment step and without the addition of a coupling agent.

11. The method of claim 10, wherein the wetting agent reacts with the proton donating moiety provided by the second lens-forming monomer in the absence of a surface oxidation treatment step and without the addition of a coupling agent.

12. The method of claim 1, wherein the medical device is an ophthalmic lens or ophthalmic implant.

13. The method of claim 11, wherein the medical device is a contact lens.

14. The method of claim 1, wherein the wetting agent includes a polymer having a carboxylic acid content of at least 30 mole percent.

15. The method of claim 1, wherein the wetting agent includes at least one member selected from the group consisting of P(vinylpyrolidinone(VP)-co-acrylic acid(AA)), P(methylvinylether-alt-maleic acid), P(acrylic acid-graft-ethyleneoxide), P(acrylic acid-co-methacrylic acid), P(acrylamide-co-AA), P(acrylamide-co-AA), P(AA-co-maleic), and P(butadiene-maleic acid).

16. The method of claim 1, wherein the wetting agent is present in a treatment solution having a pH of less than 5.